Study | Country | Age | Sex | CAT score | mMRC score | Smoking | Temperature and pollution | Prior exacerbation | BMI | 6MWD | QoL score | Race, ethnicity, or region | Comorbidities | Eosinophil count | Biomarkers | Disease severity or BDR |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adir 2018 [62] | Israel | – | – | – | – | – | – | – | – | – | – | – | – | ✔ | – | ✔a |
Alexopoulos 2015 (GOLDEN study) [28] | Greece | ✔ | ✔ | – | – | ✔ | – | – | ✔ | – | – | – | ✔ | – | – | ✔b |
Annavarapu 2018 [34] | US | – | – | – | – | ✔ | – | ✔ | – | – | – | ✔ | ✔ | – | – | – |
Bade 2019 [80] | US | ✔ | ✔ | – | – | ✔ | – | – | – | – | – | ✔ | ✔ | – | – | – |
Bafadhel 2018 [37] | Global | – | ✔ | – | – | ✔ | – | ✔ | – | – | – | – | – | ✔ | – | ✔ |
Bartels 2018 [63] | Canada | ✔ | ✔ | – | – | ✔ | – | – | – | – | – | – | ✔ | – | – | ✔a |
Baumeler 2016 (PROMISE-COPD study) [33] | EU | ✔ | – | – | ✔ | ✔ | – | – | – | ✔ | ✔ | – | ✔ | – | – | ✔a |
Calverley 2018 (TIOSPIR study) [38] | Global | – | – | – | – | – | – | ✔ [39] | – | – | – | – | – | – | – | – |
Chapman 2018 (SUNSET trial) [89] | Global | – | – | – | – | – | – | – | – | – | – | – | – | ✔ | – | – |
Couillard 2017 [90] | Canada | – | – | – | – | – | – | – | – | – | – | – | – | ✔ | – | – |
Crisafulli 2015 [35] | Spain | – | – | – | – | – | – | ✔ | – | – | – | – | ✔ | – | ✔ | – |
de Miguel-Díez 2019 [31] | Spain | – | – | – | – | – | ✔ | – | – | – | – | – | – | – | – | – |
Eklöf 2020 (e-publication, 2019) [40] | Denmark | ✔ | ✔ | – | ✔ | ✔ | – | ✔ | ✔ | – | – | – | ✔ | – | – | ✔a |
Emura 2019 [66] | Japan | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ✔b |
Engel 2017 (REDUCE study) [24] | Switzerland | ✔ | ✔ | – | ✔ | ✔ | – | – | – | – | – | – | ✔ | – | – | ✔ |
Erol 2018 [67] | Turkey | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ✔ |
Estirado 2018 [41] | Spain | – | – | – | – | ✔ | – | ✔c | – | – | – | – | ✔ | – | – | – |
Ferguson 2018 (KRONOS study) [91] | Global | – | – | – | – | – | – | – | – | – | – | – | – | ✔ | – | – |
Fuhrman 2017 [42] | France | ✔ | ✔ | – | – | – | – | ✔ | – | – | ✔ | – | – | – | – | – |
Han 2017 (SPIROMICS study) [20] | US | ✔ | ✔ | ✔ | – | ✔ [110] | – | ✔ | – | ✔ | – | ✔ | ✔ [82] | ✔ | ✔ | ✔a |
Han 2018 [68] | Taiwan | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ✔ |
Huang 2018 [69] | Taiwan | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ✔b |
Jo 2018 [18] | South Korea | ✔ | ✔ | ✔ | ✔ | – | – | ✔ | – | – | ✔ | – | – | – | – | ✔ |
Jo 2018b [27] | South Korea | ✔ | ✔ | – | – | ✔ | – | – | ✔ | – | – | – | ✔ | – | – | – |
Jung 2015 [70] | South Korea | – | – | – | – | – | – | – | – | – | ✔ | – | – | – | – | ✔a |
Kim 2017 [71] | South Korea | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ✔ |
Kim 2019 (COPDGene study) [64] | US | – | – | – | – | – | – | – | – | – | ✔ [81] | – | ✔ [81] | – | – | ✔ [65] |
Ko 2019 [92] | China | – | – | – | – | – | – | – | – | – | – | – | – | ✔ | – | – |
Kobayashi 2018 [72] | Japan | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ✔b |
Krachunov 2017 [32] | Bulgaria | – | – | – | – | – | ✔ | – | – | – | – | – | – | – | – | – |
Krachunov 2018 [43] | Bulgaria | – | – | – | ✔ | – | – | ✔ | – | – | – | – | – | – | – | ✔b |
Lau 2017 [83] | US | ✔ | ✔ | – | – | – | – | – | – | – | – | ✔ | ✔ | – | – | – |
Lee 2019 [73] (Yoon 2019) | Korea | ✔ | ✔ | ✔ | – | ✔ | – | – | – | ✔ | ✔ | – | ✔ | – | ✔ | ✔ |
Liu 2015 [29] | China | ✔ | ✔ | ✔ | ✔ | – | – | ✔ | ✔ | – | ✔ | – | – | – | – | ✔b |
MacDonald 2019 [93] | Australia | – | – | – | – | – | – | – | – | – | – | – | – | ✔ | – | – |
Make 2015 [44] | Global | ✔ | ✔ | – | ✔ | ✔ | – | ✔ | ✔ | – | ✔ | – | ✔ | – | – | ✔ |
Marçôa 2018 [19] | Portugal | – | – | ✔ | ✔ | – | – | ✔ | – | – | – | – | ✔ | – | – | ✔ |
Margüello 2016 [23] | Spain | ✔ | ✔ | – | – | ✔ | – | ✔ | ✔ | – | – | – | – | – | – | ✔ |
McGarvey 2015 [22] | UK | ✔ | ✔ | – | ✔ | ✔ | – | ✔ | – | – | – | – | ✔ | – | – | ✔a |
Montserrat-Capdevila 2015 [45] | Spain | ✔ | ✔ | – | – | ✔ | – | ✔ | – | – | – | – | ✔ | – | – | ✔b |
Montserrat-Capdevila 2016 [46] | Spain | – | ✔ | – | – | ✔ | – | ✔ | – | – | – | – | ✔ | – | – | ✔b |
Müllerová 2019 (HO-17–18,395 study) [94] | US | – | – | – | – | – | – | – | – | – | – | – | – | ✔ | – | – |
Orea-Tejeda 2018 [47] | Mexico | ✔ | ✔ | – | – | – | – | ✔ | – | – | – | – | ✔ | – | – | – |
Papi 2018 (TRIBUTE trial) [48] | Global | – | ✔ | – | – | ✔ | – | ✔ | – | – | – | – | – | ✔ | – | ✔ |
Pascoe 2019 (IMPACT trial) [13] | Global | – | – | – | – | ✔c | – | ✔c [49] | – | – | – | – | – | ✔c | – | – |
Pasquale 2016 [50] | US | – | – | ✔ | ✔ | – | – | ✔ | – | – | – | – | – | – | – | ✔ |
Pavlovic 2017 [74] | Serbia | ✔ | ✔ | – | – | ✔ | – | – | ✔ | – | – | – | ✔ | – | ✔ | ✔a |
Pavord 2016 (INSPIRE, TRISTAN, SCO30002 trials) [99] | Global | – | – | – | – | – | – | – | – | – | – | – | – | ✔c | – | – |
Pikoula 2019 [84] | UK | – | ✔ | – | – | ✔ | – | – | – | – | – | – | ✔ | – | – | – |
Roche 2017 (FLAME trial) [96] | Global | – | – | – | – | – | – | – | – | – | – | – | – | ✔c | – | – |
Rothnie 2018 [12] | UK | – | – | – | – | – | – | ✔ | – | – | – | – | – | – | – | – |
Santibáñez 2016 [26] | Spain | ✔ | ✔ | – | – | ✔ | – | ✔ | ✔ | – | – | – | ✔ | – | – | ✔b |
Schuler 2018 (RIMTCORE study) [51] | Germany | ✔ | ✔ | – | ✔ | ✔c | – | ✔ | ✔ | ✔ | ✔ | – | ✔ | – | – | ✔a |
Singh 2016 (TRILOGY trial) [52] | Global | ✔ | ✔ | – | – | ✔ | – | ✔ | – | – | – | – | ✔ | ✔ | – | ✔ |
Søgaard 2016 [53] | Denmark | – | – | – | – | – | – | ✔c | – | – | – | – | ✔ | – | – | – |
Song 2018 [75] | South Korea | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ✔b |
Stanford 2018 (HO-11–732 study) [54] | US | ✔ | – | – | – | – | – | ✔ | – | – | – | – | ✔ | – | – | – |
Stanford 2019 [55] | US | – | – | – | – | – | – | ✔ | – | – | – | – | – | – | – | – |
Sundh 2015 [76] | Sweden | – | – | – | – | ✔ | – | – | – | – | – | – | ✔ | – | – | ✔a |
Tsiligianni 2016 (UNLOCK study) [17] | Netherlands | – | – | – | – | – | – | ✔ | – | – | ✔ | – | – | – | – | – |
Urwyler 2019 [77] | Switzerland | ✔ | ✔ | – | ✔ | ✔ | – | – | ✔ | – | – | – | ✔ | – | – | ✔ |
Vedel-Krogh 2016 (Copenhagen General Population Study) [8] | Denmark | – | – | – | – | ✔ | – | ✔ [11] | – | – | – | – | – | ✔ | ✔ | ✔ |
Vestbo 2017 (TRINITY trial) [56] | Global | ✔ | ✔ | – | – | ✔ | – | ✔ | – | – | – | – | ✔ | ✔ | – | ✔ |
Vestbo 2019 [97] | Global | – | – | – | – | – | – | – | – | – | – | – | – | ✔ | – | – |
Vogelmeier 2019 [60] | US & UK | – | – | – | – | – | – | ✔ | – | – | – | – | – | ✔ | – | – |
Wallace 2019 [78] | US | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ✔b |
Watz 2016 (WISDOM trial) [98] | US | – | – | – | – | – | – | – | – | – | – | – | – | ✔c | – | – |
Wei 2017 (TOLD study) [85] | Taiwan | ✔ | ✔ | ✔ | ✔ | ✔ | – | – | ✔ | – | – | – | ✔ | – | – | – |
Wei 2018 [57] | China | – | – | – | – | – | – | ✔ | – | – | – | – | – | – | – | – |
Westerik 2017 [7] | Netherlands | – | – | – | – | – | – | – | – | – | – | – | ✔ | – | – | – |
Whalley 2019 (The Salford Lung study) [58] | UK | – | ✔ | – | – | ✔ | – | ✔ | – | – | – | – | ✔ | – | – | – |
Wu 2018 [111] | China | – | – | – | – | ✔ | – | – | ✔ | – | – | – | – | – | – | – |
Yii 2019 [21] | Singapore | ✔ | ✔ | ✔ | ✔ | ✔ | – | ✔ | ✔ | – | – | – | ✔ | – | – | – |
Yohannes 2017 (ECLIPSE study) [16] | Global | ✔ | ✔ | – | ✔ | ✔ | – | ✔ | ✔[25] | – | ✔ | – | – | ✔ | ✔ | |
Yun 2018 (ECLIPSE + COPDGene study) [14] | Global | ✔ | ✔ | – | – | ✔ | – | ✔ | – | – | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
Zeiger 2018 [59] | US | – | ✔ | – | – | ✔ | – | ✔ | – | – | – | ✔ | ✔ | ✔ | – | ✔ |